Actual compliance to adjuvant chemotherapy in gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong-Wook | - |
dc.contributor.author | Kwon, Oh Kyoung | - |
dc.contributor.author | Yoo, Moon-Won | - |
dc.contributor.author | Ryu, Seung-Wan | - |
dc.contributor.author | Oh, Sung Jin | - |
dc.contributor.author | Hur, Hoon | - |
dc.contributor.author | Hwang, Sun-Hwi | - |
dc.contributor.author | Lee, Junhyun | - |
dc.contributor.author | Jin, Sung-Ho | - |
dc.contributor.author | Lee, Sang Eok | - |
dc.contributor.author | Kim, Jong-Han | - |
dc.contributor.author | Kim, Jin-Jo | - |
dc.contributor.author | Jeong, In Ho | - |
dc.contributor.author | Jee, Ye Seob | - |
dc.date.accessioned | 2021-09-01T16:56:26Z | - |
dc.date.available | 2021-09-01T16:56:26Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-04 | - |
dc.identifier.issn | 2288-6575 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/66452 | - |
dc.description.abstract | Purpose: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer. Methods: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea. Results: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (>= 60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354); by body mass index (BMI) (>= 23 kg/m(2) vs. <23 kg/m(2)) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively. Conclusion: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m(2), and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SURGICAL SOCIETY | - |
dc.subject | PHASE-III TRIAL | - |
dc.subject | OPEN-LABEL | - |
dc.subject | STAGE-II | - |
dc.subject | SURGERY | - |
dc.subject | S-1 | - |
dc.subject | CAPECITABINE | - |
dc.subject | OXALIPLATIN | - |
dc.subject | SAFETY | - |
dc.title | Actual compliance to adjuvant chemotherapy in gastric cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong-Han | - |
dc.identifier.doi | 10.4174/astr.2019.96.4.185 | - |
dc.identifier.scopusid | 2-s2.0-85063880727 | - |
dc.identifier.wosid | 000463029800005 | - |
dc.identifier.bibliographicCitation | ANNALS OF SURGICAL TREATMENT AND RESEARCH, v.96, no.4, pp.185 - 190 | - |
dc.relation.isPartOf | ANNALS OF SURGICAL TREATMENT AND RESEARCH | - |
dc.citation.title | ANNALS OF SURGICAL TREATMENT AND RESEARCH | - |
dc.citation.volume | 96 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 185 | - |
dc.citation.endPage | 190 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002448452 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | PHASE-III TRIAL | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | STAGE-II | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordPlus | S-1 | - |
dc.subject.keywordPlus | CAPECITABINE | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Compliance | - |
dc.subject.keywordAuthor | Adjuvant chemotherapy | - |
dc.subject.keywordAuthor | Advanced gastric cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.